UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ofThe Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2020

Glaukos Corporation(Exact name of registrant as specified in its charter)

Delaware 001-37463 33-0945406(State or other jurisdiction (Commission (I.R.S. Employer

of incorporation) File Number) Identification No.)

229 Avenida Fabricante San Clemente, California 92672

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 367-9600

Not Applicable(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under anyof the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growthcompany ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class: Trading Symbol Name of each exchange on which registered:Common Stock GKOS New York Stock Exchange

Item 8.01. Other Events. Glaukos Corporation (the “Company”) intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the“Investor Presentation”) from time to time in presentations to investors and other stakeholders. The Investor Presentation will also beavailable on the investor page of the Company’s website at http://investors.glaukos.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. Exhibit No. Description99.1 Investor Presentation, dated January 2020104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on itsbehalf by the undersigned hereunto duly authorized.

GLAUKOS CORPORATION (Registrant)

By: /s/ Joseph E. Gilliam Name: Joseph E. Gilliam

Title: Chief Financial Officer and Senior Vice President,

Corporate Development Date: January 15, 2020

Exhibit 99.1

1©2020GlaukosCorporation1January2020

2©2020GlaukosCorporationDisclaimerAllstatementsotherthanstatementsofhistoricalfactsincludedinthispresentationthataddressactivities,eventsordevelopmentsthatweexpect,believeoranticipatewillormayoccurinthefutureareforward-lookingstatements.Thesestatementsarebasedonmanagement’scurrentexpectations,assumptions,estimatesandbeliefs.Althoughwebelievethatwehaveareasonablebasisforforward-lookingstatementscontainedherein,wecautionyouthattheyarebasedoncurrentexpectationsaboutfutureeventsaffectingusandaresubjecttorisks,uncertaintiesandfactorsrelatingtoouroperationsandbusinessenvironment,allofwhicharedifficulttopredictandmanyofwhicharebeyondourcontrol,thatmaycauseouractualresultstodiffermateriallyfromthoseexpressedorimpliedbyforward-lookingstatementsinthispressrelease.Thesepotentialrisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthosedescribedinforward-lookingstatementsinclude,withoutlimitation,uncertaintiesaboutourdependenceonthesuccessandmarketacceptanceoftheiStentandtheiStentinject;ourabilitytoreachsustainedprofitability;ourabilitytoleverageoursalesandmarketinginfrastructuretoincreasemarketpenetrationandacceptanceofourproductsbothintheUnitedStatesandinternationally;ourabilitytobringourpipelineproductstomarket;ourdependenceonalimitednumberofthird-partysuppliers,someofwhicharesingle-source,forcomponentsofourproducts;theoccurrenceofacripplingaccident,naturaldisasterorotherdisruptionatourprimaryfacility,whichmaymateriallyaffectourmanufacturingcapacityandoperations;maintainingadequatecoverageorreimbursementbythird-partypayorsforproceduresusingtheiStent,theiStentinjectorotherproductsindevelopment;ourabilitytoproperlytrain,andgainacceptanceandtrustfrom,ophthalmicsurgeonsintheuseofourproducts;ourabilitytosuccessfullydevelopandcommercializeadditionalproducts;ourabilitytocompeteeffectivelyinthehighlycompetitiveandrapidlychangingmedicaldeviceindustryandagainstcurrentandfuturecompetitors(includingMIGScompetitors)thatarelargepubliccompaniesordivisionsofpubliclytradedcompaniesthathavecompetitiveadvantages;thetiming,effect,expenseanduncertaintyofnavigatingdifferentregulatoryapprovalprocessesaswedevelopadditionalproductsandpenetrateforeignmarkets;theimpactofanyproductliabilityclaimsagainstusandanyrelatedlitigation;theeffectoftheextensiveandincreasingfederalandstateregulationinthehealthcareindustryonusandoursuppliers;thelengthyandexpensiveclinicaltrialprocessandtheuncertaintyoftimingandoutcomesfromanyparticularclinicaltrial;theriskofrecallsorserioussafetyissueswithourproductsandtheuncertaintyofpatientoutcomes;ourabilitytoprotect,andtheexpenseandtime-consumingnatureofprotecting,ourintellectualpropertyagainstthirdpartiesandcompetitorsthatcoulddevelopandcommercializesimilaroridenticalproducts;theimpactofanyclaimsagainstusofinfringementormisappropriationofthirdpartyintellectualpropertyrightsandanyrelatedlitigation;themarket’sperceptionofourlimitedoperatinghistoryasapubliccompany;potentialadversereactionsorchangestothebusinessrelationshipsofGlaukosandAvedrowiththeirrespectivecustomers,suppliersandothersresultingfromthecompletionoftheacquisitionofAvedro;anyunexpectedimpactsfromunforeseenliabilities,futurecapitalexpenditures,revenues,expenses,earnings,synergies,economicperformance,indebtedness,financialcondition,costsandlosseswithrespecttotheacquisitionofAvedro,includingonthefutureprospects,businessandmanagementstrategiesforthecombinedcompany’soperations;inherentrisks,costsanduncertaintiesassociatedwithintegratingthebusinessessuccessfullyandrisksofnotachievingalloranyoftheanticipatedbenefitsfromtheacquisitionofAvedroorthatsuchbenefitsmaynotbefullyrealizedortakelongertorealizethanexpected;potentialdisruptionsfromtheacquisitionofAvedrothatmaydivertmanagementattentionfromotherimportantbusinessobjectives;anddilutionofourstockholders’ownershipinterestinourcompanyinconnectionwiththeacquisitionofAvedro.Theseandotherknownrisks,uncertaintiesandfactorsaredescribedindetailunderthecaption“RiskFactors”andelsewhereinourfilingswiththeSecuritiesandExchangeCommission(the“SEC”),includingourQuarterlyReportonForm10-QforthequarterendedSeptember30,2019,whichwasfiledwiththeSEConNovember8,2019.OurfilingswiththeSECareavailableintheInvestorSectionofourwebsiteatwww.glaukos.comoratwww.sec.gov.Inaddition,informationabouttherisksandbenefitsofourproductsisavailableonourwebsiteatwww.glaukos.com.Allforward-lookingstatementsincludedinthispressreleaseareexpresslyqualifiedintheirentiretybytheforegoingcautionarystatements.Youarecautionednottoplaceunduerelianceontheforward-lookingstatementsinthispressrelease,whichspeakonlyasofthedatehereof.Wedonotundertakeanyobligationtoupdate,amendorclarifytheseforward-lookingstatementswhetherasaresultofnewinformation,futureeventsorotherwise,exceptasmayberequiredunderapplicablesecuritieslaw.

3©2020GlaukosCorporation1FY2014sales;2019salesguidancerangeprovidedon11/6/2019earningscall(excludesAvedro);2FY2014grossmargin;2019asof9/30/2019;32015asof6/30/2015(post-IPO);2019asof9/30/2019;412/31/2019includesformerAvedroemployeesBuildingaWorld-ClassGlobalInfrastructure&CompanySignificantProgressSince2015IPO$46$229-232Est.5-YrCAGR:38%20142019TOTALNETSALES(INMILLIONS)187%75%20192014GROSSMARGIN2CASH&SHORT-TERMEQUIVALENTS(INMILLIONS)320142019COUNTRIESWITHDIRECTSALES217R&DCommercialSalesUSCommercialSalesWWEmployeesWW+362%+291%+182%+282%6/30/201512/31/2019DISCLOSEDPIPELINEPROGRAMS20152019GlaucomaGlaucomaCornealHealthRetinalDisease134$162$10420192015PEER-REVIEWEDARTICLESEMPLOYEES420152019GlaucomaGlaucomaCornealHealth28533

4©2020GlaukosCorporation2019:MajorAchievementsthatStrengthenedOurLong-TermGrowthPotential…JanFebMarAprMayJunJulAugSepOctNovDec2019Completedacquisition,establishingCornealHealthfranchiseStrengthenedUSmarketleadershipwithsuccessfullaunchCompletedacquisitiontosecuremultiplenovelretinaldrugdeliveryprogramsEnteredIntratuslicensingagreementfornoveltopicaldrugdeliverysystemCompletedenrollmentinUSFDAtrialSecuredexclusiveUSagreementforPreserflo™MicroShuntReceivedJapanPMDAapproval…AndRevealedOurStrategicVisionContinuedpatientenrollmentinUSPhase3trial®™

5©2020GlaukosCorporationTransformingthetreatmentofchroniceyediseaseswithnoveltherapiesthatprovidesustainablesolutionstoimportantclinicalneeds

6©2020GlaukosCorporationMAJORPATIENTPOPULATIONSDELIVERsafe,effectivetherapiesthatoptimizevisioncareandbuilddurablefranchisestoservedoctorsandpatientsLeveragingOurCoreCompetenciestoBuild&DisruptMajorOphthalmicMarketsCreatingaUniqueVisionCareLeadertoDriveLong-TermGrowth&Profitability3ROBUSTTECHNOLOGYPLATFORMS3GlaucomaCornealHealthRetinalDiseaseMicro-SurgicalDevicesSustainedPharmaceuticalsImplantableBiosensorsDEPLOYexpertiseproventostimulateadoption,enhancecustomersuccessandpromotestrong,enduringmarketsPOWERFULCORECOMPETENCIES3PioneeringDisciplineSkilledCommercializationPipelineDevelopmentDISRUPTtreatmentparadigmsbyimprovingoutcomes,patientquality-of-lifeandvaluetohealthcaresystem

7©2020GlaukosCorporationGlaucoma

8©2020GlaukosCorporationGlaucomaOverviewChronicDiseaseisSecond-LeadingCauseofBlindnessWorldwideGlaucomaPortfolio1Micro-SurgicalDevicesSustainedPharmaceuticalsImplantableBiosensorsiStent®iStentinject®SantenPreserflo™iStentinfinite™iStent®SAiDose®TRiDose®TREXiDose®RockIOPSensor1iStentSA,iStentinfinite,SantenPreserflo,iDoseTR,iDoseTREX,iDoseRockandIOPSensorarenotapprovedbytheFDA;2CompanyestimateofOHT/POAGbasedon2017analysisofdatafromMarketScope,Medicareclaims,IMSandothersources;3EstimatebasedonGlaukosalgorithmofphysicianpreferenceandcombinationtherapy,utilization;assumesfullproductportfolioavailabilitytophysician,exceptpre-clinicalproducts(iDoseTREX,iDoseRock,IOPSensor)OCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYGlaucomaProgression~8MDiagnosedUSeyes,growing3-4%/year2•Progressive,irreversibledisease;HispanicandAfrican-Americanpopulationsathigherrisk;controllingIOPisonlytreatment•Topicalmedicationsarestandardofcarebutnon-adherenceisubiquitous•Approximatelyhalfofallpatientsrequire2ormoremedsProvidenoveltherapiestoaddressfullrangeofdiseaseprogression$13BOUROPPORTUNITYOURAPPROACHEst.globalopportunity3

9©2020GlaukosCorporationGlaucomaMicro-SurgicalDevicesIndustry’sMostComprehensiveOfferingDesignedtoAddressFullRangeofDiseaseProgressionApproved20182multi-directionaltrabecularmeshworkstentsinautoinjectionsystemApprovalTarget20213multi-directionaltrabecularmeshworkstentsinautoinjectionsystemNovelinsertionsystemallowsplacementacross5-6clockhoursofSchlemm’scanalApprovalTarget20232multi-directionaltrabecularmeshworkstentsinautoinjectionsystemApprovalTarget2020-21Ab-externodeviceforlate-stageglaucomaSanten’sexclusiveUSpartnerINTENDEDDISEASESTATEMildtoModerateAdvancedtoRefractoryiStentSA,iStentinfiniteandSantenPreserfloarenotapprovedbytheFDAApproved2012TrabecularmeshworkstentinautoinjectionsystemCombo-CataractStandalone®™™

10©2020GlaukosCorporationGlaucomaSustainedPharmaceuticalsDesignedtoBeViableAlternativetoTopicalMedications,AddressingNon-AdherenceandOtherDrawbacksINTENDEDDISEASESTATEOcularHypertensiontoModerateOAGTitaniumimplantdesignedforcontinuousdrugdeliverydirectlyintoanteriorchamberMembraneelutesspeciallyformulatedtravoprost,mostcommonlyprescribedtopicalprostaglandinCurrentlyenrollingpatientsinPhase3clinicaltrialsTimololgrouprequired31%moremedicationsonaverage,comparedtoiDosecohortsAverageIOPReductionsfromBaselinethroughMonth12*USPhaseIIPreliminaryEfficacyResultsiDoseTRisnotapprovedbytheFDA®

11©2020GlaukosCorporationGlaucomaSustainedPharmaceuticalsNext-GenerationiDoseTREXDesignedforIncreasedDrugPayload&Duration-of-EffectINTENDEDDISEASESTATEOcularHypertensiontoModerateOAGSubstantialincreaseindrugpayload,withpotentialtodoubletheduration-of-effectvsfirst-generationiDoseSametitaniummaterial,elutionrate,anchordesignandimplantationprocedureasfirst-generationiDoseUsestravoprostformulationidenticaltofirst-generationiDoseCurrentlyevaluatingregulatoryapprovalpathwaysiDoseTRandiDoseTREXarenotapprovedbytheFDA®®®

12©2020GlaukosCorporationGlaucomaSustainedPharmaceuticalsPotentialtoLeverageiDosePlatformwithNovelROCKInhibitorCompoundsiDoseRockisnotapprovedbytheFDAR&DteamsfocusedondrugcharacteristicsandpredictabilityfordeliveryviaiDosesystemSmall-moleculeAPIs,highpotency,lowaqueoussolubilityReceptordoesnotlosesensitivityduringlong-termdosing,molecularstructurechemicallystableovertimePotentialforreducedsideeffectsvstopicaldeliveryD.WesternTherapeuticscollaborationprogressingAbilitytoaccessDWTI’sROCKinhibitorcompoundlibraryandpotentialnewcompoundsCertainexclusiverightstodevelopnovelproductsusingcompoundsScreeningofmultiplecompoundsdemonstratedgoodIOPreductioninrabbitmodels;prototypeimplantdevelopmentforleadcandidatesunderway

13©2020GlaukosCorporationPRE-CLINICALINITIALTRIALPIVOTALTRIALFDASUBMISSIONAPPROVAL/TARGETIOPSensorGlaucomaSummaryGlaucomaPortfolioMicro-SurgicalDevicesSustainedPharmaceuticalsPRE-CLINICALINITIALTRIALPIVOTALTRIALFDASUBMISSIONAPPROVAL/TARGETiStent2012iStentinject2018SantenPreserflo2020-21iStentinfinite2021iStentSA2023ESTIMATEDANNUALUSOPPORTUNITYPRE-CLINICALPHASE1PHASE2PHASE3FDASUBMISSIONAPPROVAL/TARGETiDoseTR2022iDoseTREXiDoseRockImplantableBiosensors4.3iStentSA,iStentinfinite,SantenPreserfloiDoseTR,iDoseTREX,iDoseRockandIOPsensorarenotapprovedbytheFDA(Eyes,inmillions)0.6+3.0MarketopportunityestimatesbasedonGlaukosalgorithmofphysicianpreferenceandcombinationtherapy,utilization;assumesfullproductportfolioavailabilitytophysician,exceptpre-clinicalproducts(iDoseTREX,iDoseRock,IOPSensor)Combo-cataract1.3+0.7StandalonePharma~50%ofglobalopportunity

14©2020GlaukosCorporationCornealHealth

15©2020GlaukosCorporationCornealHealthOverviewFocusedonDisruptiveSolutionsAcrossKeratoconus,Presbyopia&DryEyePatientPopulationsCornealHealthPortfolioSustainedPharmaceuticalsiLinkForKeratoconusPhotrexa®Epi-offEpi-oniLinkForPresbyopiaPiXL™ForDryEyeIntratus1.1MEyeswithkeratoconusinUS;32Knewcases/yr1•Degenerativediseaseinwhichcorneaprogressivelythinsandweakens,degradingvision;onsetofteninteenageyears•20%eventuallyrequirecornealtransplant;studiessuggestthat72%ofcornealtransplantsfailwithin20years2$3B$4BEstimatedUSopportunityforiLinkkeratoconustherapy1$15BEstimatedUSopportunityforiLinkpresbyopiatreatment1Estimatedannualrevenueinglobaldryeyemarket3OUROPPORTUNITYOURAPPROACHBuildarobustfranchiseby:•Drivingcornealcrosslinkingtostandardofcareforkeratoconus•Expandingindicationstoincludepresbyopia•Deliveringnoveltherapiesfordryeyediseaseandothercornealdisorders1CompanyestimatesofUSopportunity;2Borderie,V.etal,Predictedlong-termoutcomeofcornealtransplantation.AmericanAcademyofOphthalmology2009;3MarketScopeestimateofglobalmarketKeratoconusPresbyopiaDryEye

16©2020GlaukosCorporationCornealHealthRecentlyCompletedAvedroAcquisitionSetsCornerstoneforNewCornealHealthFranchiseSTATUSPerfectcommercialfitAcceleratesgrowthtrajectoryFurthershybridpharmastrategyEnhancesorganicpipelineinitiatives/R&DteamsCreatesshareholdervalueSTRATEGICRATIONALE/OPPORTUNITYFieldsalesandmarketaccessintegrationcomplete;resultingin>90combinedUSpersonnelfocusedon~1,100targetedaccountsAmplifyingODeducationprograms;fundinghealtheconomicstudiesGlobalscaleexpectedtodeliverrevenuesynergiesin2021+R&D,ClinicalandRegulatoryfunctionintegrationcomplete;advancingpipelineinitiativesImplementing$15Minpotentialestimatedcostsavingsin2021;expecttransactiontobeaccretiveto2021+operatingresultsandcashflowTransitionprocessledbycombinedteamwithextensiveexperienceinmajorophthalmicM&Aintegrationsanddeepcornealbusinessknowledge

17©2020GlaukosCorporationRemovingtheepithelium(Epi-offonly)SingleapplicationofPhotrexa®&Photrexa®ViscousappliedtocorneaUVilluminationisappliedPatientcorneaposttreatmentPhotrexaTherapy:FirstBio-ActivatedDrugforAnteriorSegmentDiseasePhotrexaEpi-offisFirstFDA-ApprovedCornealCrosslinkingTherapyforKeratoconusSingle-application,bio-activatedtopicalpharmaceuticalsolutionshowntohaltkeratoconusprogressionBiochemicaltechniqueutilizesphoto-activationtocreatebondsbetweeneye’scollagenfibersExcellentefficacyandsafetyprofile,extensiveclinicalevidenceandlong-term(10-year)follow-upProduct-specificJ-CodebecameeffectiveJanuary2019;favorablereimbursementsecuredfor95%+ofcommerciallivescoveredKeratoconuspresentsmajoreconomicandresourceburdentohealthcaresystem•Predominantindividualclinicaldiagnosisleadingtokeratoplasties,responsibleforover1inevery10cornealtransplantsnationwide1•Lifetime,per-patientcarecostsare$24Kmorethanprovidingcareforapersonwithmyopia21America,E.B.A.o.,2015EyeBankingStatisticalReport.2016;2Rebenitsch,R.L.,etal.,Thelifetimeeconomicburdenofkeratoconus:adecisionanalysisusingamarkovmodel.AmJOphthalmol,2011

18©2020GlaukosCorporationEpi-onTherapyNon-InvasiveTherapyOffersPotentialtoExpandKeratoconusTreatmentPopulationDesignedtoreducetreatmenttimeandcomplexity;improvespatientcomfortandfasterrecovery;expectedtodriveincreasedwillingnesstotreatpatientsearlier•Involvesaproprietary,noveldrugformulationbasedondecadesofformulationandclinicaldevelopment•StrongerUVAirradiationprotocolandspeciallydesigned“boost”gogglestoincreaseoxygenavailabilityFDAtrialenrollmentcompletedMay2019;targetingFDAapprovalby2022

19©2020GlaukosCorporationCENTRALACTIVATIONFORMYOPIAPERIPHERALACTIVATIONFORPRESBYOPIA4Single-applicationofbio-activatedtopicalophthalmicpharmaceuticalsasapotentialalternativetoLASIK,refractiveIOLsorimplantsPotentialtoprovidespectacleindependencewithminimalcompromiseStraightforwardprocedurewithminimalrecovery(1-2days)Phase2ainternationalpresbyopiatrialunderwayPiXLTherapyPotentialOne-TimeNon-InvasiveTherapyforPresbyopia&LowMyopia5

20©2020GlaukosCorporationIntratusTopicalTherapyforTreatmentofDryEye&CornealDisordersProprietarylotionappliedtoouterskinsurfaceoftheuppereyelidsAnatomyoftheeyelidwithtargetedsitesNovel,sustainedpharmaceuticalplatformtargetingdryeyeandotheroculardisordersPatented,cream-basedformulationdesignedtobeappliedtouppereyelidfordeliveryatthelacrimalfunctionalunitEasieradministrationthantopicaleyedrops,potentiallybetterpatientcomplianceEarlyhumanstudiesondryeyesubjectsshowpromisingresultsMayalsohaveapplicationsforglaucomatherapyExclusivegloballicensetoresearch,development,manufactureandcommercializetopicaltreatmentcomplementsGlaukos’organiccornealhealthR&Dinitiatives

21©2020GlaukosCorporationCornealHealthSummaryCornealHealthPortfolioSustainedPharmaceuticalsPRE-CLINICALPHASE1PHASE2PHASE3FDASUBMISSIONAPPROVAL/TARGETKeratoconusPhotrexaEpi-off2016Epi-on2022PresbyopiaPiXLDryEyeIntratus+X.X

22©2020GlaukosCorporationRetinalDisease

23©2020GlaukosCorporationRetinalDiseasePortfolioSustainedPharmaceuticalsTriamcinoloneAcetonideAnti-VEGFBiologicMulti-KinaseInhibitor29MPeopleintheUShaveretinaldisease1•AMDanddiabeticeyediseasemakeup89%ofallretinaldiseaseandareleadingcausesofblindness•AMDaffectscentralvision;incidenceriseswithage•Roughly40%ofdiabeticsinUShavesomediabeticretinopathyGlobalrevenuesexceed$13BgrowingatCAGRof9.6%through20231Intravitrealanti-VEGFinjections,intendedforadministration7-12timesperyear2,arecurrentUSAMDstandardofcareOUROPPORTUNITYOURAPPROACHPursuedevelopmentofmultiplemicro-invasive,bio-erodibledrugdeliveryprogramsfocusedonAMD,diabeticmacularedemaandotherretinaldiseasesTargettreatmentoptionswithmeaningfullylongerduration-of-effectthancurrentstandardofcare1MarketScope;2Lucentis®andEylea®prescribinginformationRetinalDiseaseOverviewFocusedonSustainedReleaseCandidateswithImprovedDuration-of-Effect

24©2020GlaukosCorporationRetinalDiseaseProgramsSustainedReleaseCandidateforDMEShowsEarlyPromiseTriamcinoloneAcetonideFormulationsdevelopedtoreleasetriamcinoloneacetonideforupto6monthsComparisonofGlaukostriamcinoloneacetonideimplantwithtypicalintravitrealimplantsGlaukostriamcinoloneimplant:350µmdiaTypicalsteroidimplant:about460µmdiaEstimated$300Mglobalmarket11MarketScope

25©2020GlaukosCorporationRetinalDiseaseProgramsTwoSustainedReleaseCandidatesforWetAMDUnderDevelopmentAnti-VEGFBiologicDevelopingsustainedrelease,hydrogel-based,erodibleimplantwithproteinstabilizationtechnologyReleaserateofanti-VEGFproteinverifiedinanimalmodelofpersistentretinalvascularleakageOptimizationofthedeliverysystemisunderwayAnti-VEGFloadedhydrogelimplantin25-gaugestainlesssteelcannulaMulti-KinaseInhibitorFormulationsdevelopedfor6monthsreleaseanderosionPrototype4-monthimplantdemonstratedpromisinginitialefficacyinatranslationalmodelofpersistentretinalvesselleakagefollowingasingleintravitrealinjection

26©2020GlaukosCorporationMARKETOPPORTUNITY2015-20192020-222023-242025+CreatingaUniqueVisionCareLeaderMovingBeyondCombo-CataractMIGStoDriveLong-TermGrowth&ProfitabilityiStent(cc)iStentinject(cc)PhotrexaEpi-offPreserfloiStentinfiniteEpi-oniDoseTRiDoseRockIOPSensorPiXLDryEyeTherapyRetinalDiseasePrograms+Multipleadditionalundisclosedpre-clinicalR&DprogramsiStentSAiDoseTREXcc=combocataract

27©2020GlaukosCorporation27